1. Search Result
Search Result
Targets Recommended: HCV HBV
Results for "

hepatitis

" in MCE Product Catalog:

108

Inhibitors & Agonists

1

Screening Libraries

3

Peptides

13

Natural
Products

5

Recombinant Proteins

5

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas
  • HY-P1774
    Hepatitis B Virus Core (128-140)

    HBV Infection
    Hepatitis B Virus Core (128-140) is a peptide of hepatitis B virus core protein.
  • HY-P2502
    Hepatitis Virus C NS3 Protease Inhibitor 2

    HCV Protease HCV Infection
    Hepatitis Virus C NS3 Protease Inhibitor 2 is a product-based peptide inhibitor of hepatitis C virus (HCV) NS3 protease, with a Ki of 41 nM.
  • HY-121513
    Torcitabine

    2'-Deoxy-L-cytidine

    HBV Infection
    Torcitabine (2'-Deoxy-L-cytidine) is an antiviral agent. Torcitabine has the potential for chronic hepatitis B virus infection treatment.
  • HY-W018791
    Bifendate

    DDB

    HBV Infection
    Bifendate (DDB) is a synthetic intermediate of Schisandrin C with anti-HBV efficacy in research of chronic hepatitis B.
  • HY-N0639
    Punicalin

    HBV Infection Inflammation/Immunology
    Punicalin is a hydrolyzable tannin isolated from Punica granatum L. or the leaves of Terminalia catappa L.. Punicalin is a anti-hepatitis B virus (HBV) agent and has anti-inflammatory activity.
  • HY-Y0073
    4-Hydroxyacetophenone

    P-hydroxyacetophenone

    HBV Infection Inflammation/Immunology
    4-Hydroxyacetophenone (P-hydroxyacetophenone) is a key hepatoprotective and choleretic compound in Artemisia capillaris and A. morrisonensis, also has an anti-hepatitis B virus effect and anti-inflammatory effect.
  • HY-133721
    Chamaechromone

    HBV Infection Inflammation/Immunology
    Chamaechromone is a biflavonoid ingredient isolated from the roots of Stellera chamaejasme L. (Thymelaeaceae). Chamaechromone possesses anti-hepatitis B virus (HBV) effects against the surface antigen of HBV (HBsAg) secretion and has insecticidal activities.
  • HY-109137
    Selgantolimod

    GS-9688

    Toll-like Receptor (TLR) HBV Infection
    Selgantolimod (GS-9688) is an orally active, potent and selective toll-like receptor 8 (TLR8) agonist for the treatment of hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infection.
  • HY-126970
    HBF-0259

    HBV Infection
    HBF-0259 is a potent and selective inhibitor of hepatitis B virus (HBV) surface antigen (HBsAg) secretion, with an EC50 of 1.5 μM in HepG2.2.15 cells. HBF-0259 has no effect on HBV DNA synthesis.
  • HY-116999
    IR415

    HBV Infection
    IR415 is a potent anti-HBV agent and inhibits HBV replication by blocking the HBx activity. IR415 selectively interacts with HBx (Kd=2 nM) and blocks HBV-mediated RNAi suppression, reverses the inhibitory effect of HBx protein on the activity of the dicer endoribonuclease. HBx: hepatitis B virus X protein.
  • HY-13337
    BMS-986094

    INX-08189

    HCV Infection
    BMS-986094 (INX-08189) is a potent inhibitor of hepatitis C virus (HCV) replication, with an EC50 of 35 nM at 24 h in Huh-7 cells. BMS-986094 is a phosphoramidate prodrug of 6-O-methyl-2’-C-methyl guanosine. BMS-986094 can be used for the research of chronic HCV infection.
  • HY-126033
    Sophoranol

    HBV RSV Infection
    Sophoranol is an alkaloid that can be isolated from S. flavescens, with antiviral activity. Sophoranol has anti-HBV (hepatitis B virus) activity. Sophoranol shows potent antiviral activities against respiratory syncytial virus (RSV) with an IC50 of 10.4 μg/mL.
  • HY-10300
    Narlaprevir

    SCH 900518

    HCV HCV Protease SARS-CoV Infection
    Narlaprevir (SCH 900518) is a selective and orally bioavailable NS3 protease inhibitor with a Ki value of 6 nM and an EC90 value of 40 nM. Narlaprevir also inhibits the HCV nonstructural protein 3 serine protease. Narlaprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.3 μM.
  • HY-B0766
    Bicyclol

    SY801

    HBV Autophagy Infection Cancer
    Bicyclol(SY 801) is a anti-hepatitis drug.
  • HY-B0376
    Mecarbinate

    Dimecarbin; Dimecarbine; Dimekarbin

    HCV Infection
    Mecarbinate is an anti-hepatitis C virus (HCV) agent.
  • HY-13910A
    Tenofovir hydrate

    GS 1278 hydrate; PMPA hydrate

    HIV Reverse Transcriptase Infection
    Tenofovir hydrate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.
  • HY-19447A
    Besifovir Dipivoxil maleate

    LB80380 maleate

    HBV Infection
    Besifovir Dipivoxil maleate (LB80380 maleate) is an oral prodrug of LB80317. Besifovir Dipivoxil maleate (LB80380 maleate) is effective in hepatitis B virus (HBV) DNA suppression for both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients in preliminary studies[2]
  • HY-112564
    JNJ-632

    HBV Infection
    JNJ-632 is a hepatitis B virus (HBV) capsid assembly modulator (CAM).
  • HY-13910B
    Tenofovir maleate

    GS 1278 maleate; PMPA maleate

    HIV Reverse Transcriptase Infection
    Tenofovir Disoproxil Fumarate is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.
  • HY-126128
    Heliotrine

    Others Cancer
    Heliotrine is a monoester pyrrolizidine alkaloid and is used for obtaining models of hepatitis and cirrhosis of the liver.
  • HY-100029
    Bay 41-4109

    HBV Infection
    BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.
  • HY-13782
    Tenofovir Disoproxil fumarate

    Tenofovir DF; Bis(POC)-PMPA fumarate; GS 4331 fumarate

    HIV Reverse Transcriptase HBV Infection
    Tenofovir Disoproxil fumarate is a nucleotide reverse transcriptase inhibitor used to treat HIV and chronic Hepatitis B.
  • HY-77651
    Nucleoside-Analog-1

    Nucleoside Antimetabolite/Analog HCV Infection
    Nucleoside-Analog-1 is a 4′-Azidocytidine analogue against Hepatitis C virus replication.
  • HY-50680
    HCVP-IN-1

    HCV Protease Infection
    HCVP-IN-1 (compound 1) is a hepatitis C viral polymerase (HCVP) inhibitor.
  • HY-12559
    Alisporivir

    Debio-025; DEB-025

    HCV Infection
    Alisporivir (Debio-025) is a cyclophilin inhibitor molecule with potent anti-hepatitis C virus (HCV) activity.
  • HY-13782A
    Tenofovir Disoproxil

    Bis(POC)-PMPA; GS 4331

    HIV Reverse Transcriptase HBV Cancer
    Tenofovir Disoproxil (Bis(POC)-PMPA) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B.
  • HY-77652
    Nucleoside-Analog-2

    Nucleoside Antimetabolite/Analog HCV Infection
    Nucleoside-Analog-2 is a 4'-Azidocytidine analogue against Hepatitis C virus (HCV) replication.
  • HY-I0726
    Enantiomer of Sofosbuvir

    Others Infection
    Enantiomer of Sofosbuvir is an enantiomer of Sofosbuvir, a prescription medicine for the treatment of patients with chronic hepatitis C. There is no biological activity report on enantiomer of Sofosbuvir until now.
  • HY-14775
    Nesbuvir

    HCV-796

    HCV Infection
    Nesbuvir is a nonnucleoside inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase.
  • HY-13910
    Tenofovir

    GS 1278; PMPA

    Reverse Transcriptase HIV HBV Infection
    Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV).
  • HY-19512
    ACH-806

    GS9132

    HCV Protease HCV Infection
    ACH-806 is an NS4A antagonist which can inhibit Hepatitis C Virus (HCV) replication with an EC50 of 14 nM.
  • HY-124600
    NVR 3-778

    HBV Infection
    NVR 3-778 is a first-in-Class and oral bioavailable HBV CAM (capsid assembly modulator) belonging to the SBA (sulfamoylbenzamide) class, with anti-HBV activity.
  • HY-B0017
    Telbivudine

    Epavudine; L-Thymidine; NV 02B

    HBV Infection
    Telbivudine (Epavudine), an orally active thymidine nucleoside analog, is a potent antiviral inhibitor of hepatitis B virus (HBV) replication.
  • HY-100029A
    Bay 41-4109 racemate

    HBV Infection
    BAY 41-4109 racemate is the racemate of BAY 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.
  • HY-15231
    PSI-352938

    PSI-938

    HCV Infection
    PSI-352938 (PSI-938) is a hepatitis C virus (HCV) nucleotide inhibitor.
  • HY-18564
    HCV-IN-3

    HCV Infection
    HCV-IN-3 is a hepatitis C virus (HCV) NS3/4a protein inhibitor, with an IC50 of 20 μM, a Kd of 29 μM.
  • HY-107433
    U18666A

    HCV Infection Neurological Disease
    U18666A, an intra-cellular cholesterol transport inhibitor, inhibits replication of Ebola virus, dengue virus, and human hepatitis C virus.
  • HY-108060
    Valopicitabine

    NM283

    HIV Infection
    Valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2'-C-methylcytidine, acts as a promising antiviral agent for reasearch of chronic HCV infection.
  • HY-136266
    HCV-IN-29

    HCV Cancer
    HCV-IN-29 is a hepatitis C virus (HCV) inhibitor exacted from patent US8329159B2, compound 1e.
  • HY-15005B
    Sofosbuvir impurity C

    Others Others
    Sofosbuvir impurity C is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
  • HY-I0727
    Sofosbuvir impurity E

    Others Others
    Sofosbuvir impurity E is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
  • HY-101954
    Inarigivir

    ORI-9020; SB-9000

    HBV Infection
    Inarigivir (ORI-9020;SB-9000) is a dinucleotide which can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus.
  • HY-W074930
    (S)-Tenofovir

    (S)-GS 1278; (S)-PMPA; (S)-TDF

    HIV HBV Infection
    (S)-Tenofovir ((S)-GS 1278) is the less active S-enantiomer of Tenofovir. Tenofovir is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV).
  • HY-I0719
    Sofosbuvir impurity B

    Others Others
    Sofosbuvir impurity B is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
  • HY-I0723
    Sofosbuvir impurity D

    Others Others
    Sofosbuvir impurity D is an impurity of Sofosbuvir, Sofosbuvir is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
  • HY-I1196
    Sofosbuvir impurity L

    HCV Infection
    Sofosbuvir impurity L, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
  • HY-15005C
    Sofosbuvir impurity A

    HCV Infection
    Sofosbuvir impurity A, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
  • HY-15602B
    Ledipasvir D-tartrate

    GS-5885 D-tartrate

    HCV Infection
    Ledipasvir D-tartrate is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
  • HY-100029B
    Bay 41-4109 (less active enantiomer)

    HBV Infection
    Bay 41-4109 less active enantiomer shows less activity than Bay 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.
  • HY-I0515
    Sofosbuvir impurity K

    HCV Infection
    Sofosbuvir impurity K, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
  • HY-I0512
    Sofosbuvir impurity I

    HCV Infection
    Sofosbuvir impurity I, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
  • HY-I0513
    Sofosbuvir impurity N

    HCV Others
    Sofosbuvir impurity N, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
  • HY-I0938
    Sofosbuvir impurity H

    HCV Infection
    Sofosbuvir impurity H, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
  • HY-I0975
    Sofosbuvir impurity J

    HCV Infection
    Sofosbuvir impurity J, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
  • HY-I0735
    Sofosbuvir impurity M

    HCV Infection
    Sofosbuvir impurity M, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
  • HY-I0406
    Sofosbuvir impurity F

    HCV Infection
    Sofosbuvir impurity F, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
  • HY-I0408
    Sofosbuvir impurity G

    Others Others
    Sofosbuvir impurity G, an diastereoisomer of Sofosbuvir, is the impurity of Sofosbuvir. Sofosbuvir (PSI-7977) is an inhibitor of HCV RNA replication, demonstrates potent anti-hepatitis C virus activity.
  • HY-B0250
    Lamivudine

    BCH-189

    HIV Reverse Transcriptase Infection
    Lamivudine (BCH-189) is a nucleoside reverse transcriptase inhibitors (NRTIs). Lamivudine (BCH-189) can inhibit HIV reverse transcriptase 1/2 and also the reverse transcriptase of hepatitis B virus.
  • HY-19447
    Besifovir

    LB80331

    HBV Infection
    Besifovir (LB80331), a parent drug converted by LB80380, further metabolizes to its active form, LB80317. LB80380 is potent antiviral agent against hepatitis B virus (HBV) .
  • HY-13997
    Ombitasvir

    ABT-267

    HCV Infection
    Ombitasvir is a potent inhibitor of the hepatitis C virus protein NS5A, with EC50s of 0.82 to 19.3 pM against HCV genotypes 1 to 5, and 366 pM against genotype 6a.
  • HY-15789
    Elbasvir

    MK-8742

    HCV Infection
    Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) inhibitor with EC50s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.
  • HY-106235
    LB80317

    HBV DNA/RNA Synthesis Infection
    LB80317 is an active metabolite of LB80380 and suppresses the DNA synthesis of HBV with an EC50 of 0.5 μM. LB80317 has antiviral effect and has the potential for chronic hepatitis B treatment.
  • HY-10468
    NM107

    2'-C-Methylcytidine; NM-107

    HCV Infection
    NM107 (2'-C-Methylcytidine) is an nucleoside inhibitor of the hepatitis C virus (HCV) NS5B polymerase, the EC50 of NM107 in the wild-type replicon cells is 1.85 μM.
  • HY-P0025
    NIM811

    (Melle-4)cyclosporin; SDZ NIM811

    Mitochondrial Metabolism HCV Infection Inflammation/Immunology
    NIM811 ((Melle-4)cyclosporin; SDZ NIM811) is an orally bioavailable mitochondrial permeability transition and cyclophilin dual inhibitor, which exhibits potent in vitro activity against hepatitis C virus (HCV) .
  • HY-113904S
    (Rac)-Tenofovir-d6

    Reverse Transcriptase HIV HBV Infection
    (Rac)-Tenofovir-d6 ((Rac)-GS 1278-d6) is a labelled racemic Tenofovir. Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV).
  • HY-15602D
    Ledipasvir (diacetone)

    GS-5885 diacetone

    HCV Infection
    Ledipasvir diacetone (GS-5885 diacetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
  • HY-15872A
    FTI-277 hydrochloride

    Farnesyl Transferase Apoptosis Ras Cancer Infection
    FTI-277 hydrochloride is an inhibitor of farnesyl transferase (FTase); a highly potent Ras CAAX peptidomimetic which antagonizes both H- and K-Ras oncogenic signaling. FTI-277 hydrochloride can inhibit hepatitis delta virus (HDV) infection.
  • HY-15602A
    Ledipasvir (acetone)

    GS-5885 acetone

    HCV Infection
    Ledipasvir acetone (GS-5885 acetone) is the active ingredient of Ledipasvir. Ledipasvir is an inhibitor of the hepatitis C virus NS5A, with EC50 values of 34 pM against GT1a and 4 pM against GT1b replicon.
  • HY-15872
    FTI-277

    Farnesyl Transferase Apoptosis Ras Cancer Infection
    FTI-277 is an inhibitor of farnesyl transferase (FTase); a highly potent Ras CAAX peptidomimetic which antagonizes both H- and K-Ras oncogenic signaling. FTI-277 can inhibit hepatitis delta virus (HDV) infection.
  • HY-15005A
    PSI-7976

    HCV Infection
    PSI-7976 is the isomer of PSI-7977. PSI-7977 is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
  • HY-N6073
    Soyasapogenol A

    Apoptosis Inflammation/Immunology
    Soyasapogenol A, a triterpene compound, isolated from the roots of Abrus cantoniensis. Soyasapogenol A directly prevents apoptosis of hepatocytes, and secondly, inhibits the elevation of plasma TNF-α, which consequently results in the prevention of liver damage in the Concanavalin A-induced hepatitis model.
  • HY-12429
    Beclabuvir

    BMS-791325

    HCV Infection
    Beclabuvir is an allosteric inhibitor that binds to thumb site 1 of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, and inhibits recombinant NS5B proteins from HCV genotypes 1, 3, 4, and 5 with IC50 of < 28 nM. 
  • HY-15005S1
    Sofosbuvir D6

    PSI-7977 D6; GS-7977 D6

    HCV Infection
    Sofosbuvir D6 (PSI-7977 D6) is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
  • HY-109035
    Inarigivir soproxil

    SB9200

    HCV Infection
    Inarigivir soproxil is an agonist of innate immunity and shows potent antiviral activity against resistant hepatitis C virus (HCV) variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems.
  • HY-135330
    Lamivudine 13C,15N2

    HIV Reverse Transcriptase Infection
    Lamivudine 13C,15N2 is a labelled impurity of Lamivudine (BCH-189). Lamivudine is a nucleoside reverse transcriptase inhibitors (NRTIs), and can inhibit HIV reverse transcriptase 1/2 and the reverse transcriptase of hepatitis B virus.
  • HY-14434
    Asunaprevir

    BMS-650032

    HCV HCV Protease SARS-CoV Infection
    Asunaprevir (BMS-650032) is a potent and orally bioavailable hepatitis C virus (HCV) NS3 protease inhibitor, with IC50 of 0.2 nM-3.5 nM. Asunaprevir inhibits SARS-CoV-2 3CL pro activity.
  • HY-N7121
    Erythromycin estolate

    Bacterial Infection
    Erythromycin estolate, erythromycin derivative, is a macrolide antibiotic used in the treatment of a wide variety of bacterial infections. Erythromycin estolate causes several cases of liver injury which mostly include cholestatic hepatitis. Erythromycin estolate toxicity is related to its inhibitory effect on bile acid transport.
  • HY-15136
    Lonafarnib

    Sch66336

    Farnesyl Transferase Ras Autophagy Cancer Infection
    Lonafarnib (Sch66336) is a potent and orally active farnesyl transferase (FTase) inhibitor. Lonafarnib inhibits the activities of H-ras, K-ras and N-ras with IC50 values of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib also has anti-hepatitis delta virus (HDV) activities.
  • HY-15005S
    Sofosbuvir 13CD3

    PSI-7977 13CD3; GS-7977 13CD3

    HCV Infection
    Sofosbuvir 13CD3 (PSI-7977 13CD3) is the deuterium labeled Sofosbuvir. Sofosbuvir (PSI-7977) is an active inhibitor of HCV RNA replication in the HCV replicon assay, demonstrates potent anti-hepatitis C virus (HCV) activity.
  • HY-15602
    Ledipasvir

    GS-5885

    HCV SARS-CoV Infection
    Ledipasvir (GS-5885) is an inhibitor of the hepatitis C virus NS5A, with EC50s of 34 pM and 4 pM against genotype 1a and 1b replicon, respectively. Ledipasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 1.62 μM.
  • HY-19921
    JTK-853

    HCV Infection
    JTK-853 is a novel, non-nucleoside Hepatitis C Virus (HCV) polymerase inhibitor which shows effective antiviral activity in HCV replicon cells with EC50s of 0.38 and 0.035 µM in genotype 1a H77 and 1b Con1 strains, respectively.
  • HY-N0820
    Catalpol

    Catalpinoside

    HBV Cancer Infection Inflammation/Immunology Neurological Disease
    Catalpol (Catalpinoside), an iridoid glycoside found in Rehmannia glutinosa. Catalpol has neuroprotective, hypoglycemic, anti-inflammatory, anti-cancer, anti-spasmodic, anti-oxidant effects and anti-HBV effects.
  • HY-N0854
    Alisol F

    HBV Infection
    Alisol F is a triterpene isolated from Alisma orientalis, has immunosuppressive and anti-virus functions. Alisol F exhibits inhibitory activity in vitro on hepatitis B virus (HBV) surface antigen (HBsAg) secretion of the HepG2.2.15 cell line with an IC50 of 0.6 μM.
  • HY-125033
    EIDD-1931

    β-D-N4-hydroxycytidine; NHC

    SARS-CoV Enterovirus HCV Topoisomerase Infection
    EIDD-1931 (Beta-d-N4-hydroxycytidine; NHC) is a novel nucleoside analog and behaves as a potent anti-virus agent. EIDD-1931 effectively inhibits the replication activity of venezuelan equine encephalitis virus (VEEV), Chikungunya virus (CHIKV) and hepatitis C virus (HCV).
  • HY-141720
    Triton X-45(n=4)

    Others Others
    Triton X-45 (n=4), a nonionic surfactant with a low hydrophile-lypophile balance (HLB) value and dispersible in aqueous solution at room temperature, has a Krafft point above the room temperature. Triton X-45 has the potential for the research of the hepatitis C virus (HCV).
  • HY-10545
    Taribavirin

    HBV HCV Infection
    Taribavirin is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin, is a ribavirin prodrug, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia.
  • HY-12530
    Velpatasvir

    GS-5816

    HCV SARS-CoV Cancer
    Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM.
  • HY-10545A
    Taribavirin hydrochloride

    HBV HCV Infection
    Taribavirin hydrochloride is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin hydrochloride is a Ribavirin prodrug, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia.
  • HY-A0060
    Malotilate

    NKK 105

    Lipoxygenase Cancer
    Malotilate (NKK 105), an orally active hepatotropic agent and an anti-fibrotic substance, selectively inhibits the 5-lipoxygenase (5-LOX) (IC50=4.7 μM). Malotilate prevents the development of hepatocytic injury in alcohol-pyrazole hepatitis by decreasing hepatic acetaldehyde levels and preventing the retention of transferrin in the hepatocytes.
  • HY-N9451
    Ginger extract

    NF-κB Cancer Inflammation/Immunology
    Ginger extract exhibits anti-cancer, anti-inflammatory and chemotherapeutic effects in vivo.
  • HY-104077
    Remdesivir

    GS-5734

    DNA/RNA Synthesis SARS-CoV Infection
    Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro.
  • HY-N6939
    Pseudolaric Acid B

    HBV Fungal Apoptosis Autophagy Ferroptosis Cancer Infection Inflammation/Immunology
    Pseudolaric Acid B is a diterpene isolated from the root of Pseudolarix kaempferi Gorden (pinaceae), has anti-cancer, antifungal, and antifertile activities, and shows immunosuppressive activity on T lymphocytes. Pseudolaric Acid B inhibits hepatitis B virus (HBV) secretion through apoptosis and cell cycle arrest. Pseudolaric Acid B induces autophagy.
  • HY-100028
    AT-130

    HBV DNA/RNA Synthesis Cancer Infection
    AT-130, a phenylpropenamide derivative, is a potent hepatitis B virus (HBV) replication non-nucleoside inhibitor. AT-130 inhibits the viral DNA synthesis with an EC50 of 0.13 μM. AT-130 inhibits both wt and mutant HBVs. AT-130 has anti-HBV activity in hepatoma cells.
  • HY-135867D
    NHC-diphosphate

    Endogenous Metabolite Enterovirus HCV Topoisomerase SARS-CoV Infection
    NHC-diphosphate is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a diphosphate form. NHC is a pyrimidine ribonucleoside and behaves as a potent anti-virus agent. NHC effectively inhibits the replication of venezuelan equine encephalitis virus (VEEV), Chikungunya virus (CHIKV)  and hepatitis C virus (HCV).
  • HY-N0063
    Punicalagin

    SARS-CoV HBV Cancer Infection Metabolic Disease
    Punicalagin is a polyphenol ingredient isolated from Pomegranate (Punica granatum L.) or the leaves of Terminalia catappa L.. Punicalagin is a reversible and non-competitive 3CL pro inhibitor and inhibits SARS-CoV-2 replication in vitro. Punicalagin is an anti-hepatitis B virus (HBV) agent and has antioxidant, anti-inflammatory, and anticancer effects. Punicalagin has the potential for the research of COVID-19.
  • HY-126113
    KIN101

    Influenza Virus HCV Infection
    KIN101 is a potent RNA viral inhibitor with IC50s of 2 μM, >5 μM for influenza virus and Dengue virus (DNV), respectively. KIN101, an isoflavone agonist of IRF-3 dependent signaling, induces IRF-3 nuclear translocation. KIN101 has broad-spectrum activity against RNA viruses.
  • HY-12530S
    Velpatasvir-d7

    HCV SARS-CoV Cancer
    Velpatasvir-d7 (GS-5816-d7) is the deuterium labeled Velpatasvir. Velpatasvir (GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 2.16 μM.
  • HY-104077S
    Remdesivir-D5

    GS-5734-D5

    DNA/RNA Synthesis SARS-CoV Infection
    Remdesivir-D5 (GS-5734-D5) is a deuterium labeled Remdesivir. Remdesivir (GS-5734) is a nucleoside analogue, with effective antiviral activity, with EC50s of 74 nM for SARS-CoV and MERS-CoV in HAE cells, and 30 nM for murine hepatitis virus in delayed brain tumor cells. Remdesivir is highly effective in the control of 2019-nCoV (COVID-19) infection in vitro.
  • HY-15298C
    Grazoprevir sodium salt

    MK-5172 sodium salt

    HCV HCV Protease SARS-CoV Infection
    Grazoprevir sodium salt (MK-5172 sodium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively. Grazoprevir sodium salt inhibits SARS-CoV-2 3CL pro activity.
  • HY-15298B
    Grazoprevir hydrate

    MK-5172 hydrate

    HCV HCV Protease SARS-CoV Infection
    Grazoprevir hydrate (MK-5172 hydrate) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively. Grazoprevir hydrate inhibits SARS-CoV-2 3CL pro activity.
  • HY-15298
    Grazoprevir

    MK-5172

    HCV Protease HCV SARS-CoV Infection
    Grazoprevir (MK-5172) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively. Grazoprevir inhibits SARS-CoV-2 3CL pro activity.
  • HY-15298A
    Grazoprevir potassium salt

    MK-5172 potassium salt

    HCV HCV Protease SARS-CoV Infection
    Grazoprevir potassium salt (MK-5172 potassium salt) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively. Grazoprevir potassium salt inhibits SARS-CoV-2 3CL pro activity.
  • HY-125728
    Micrococcin P1

    Bacterial Parasite HCV Infection
    Micrococcin P1 is a macrocyclic peptide antibiotic and is a potent hepatitis C virus (HCV) inhibitor with an EC50 range of 0.1-0.5 μM. Micrococcin P1 has in vitro antibacterial activity against Gram-positive bacterial strains. The MIC values of Micrococcin P1 against S. aureus 1974149, E. faecalis 1674621 and S. pyogenes 1744264 are 2 μg/mL, 1 μg/mL and 1 μg/mL, respectively. Micrococcin P1 is also a potent inhibitor of the malaria parasite Plasmodium falciparum.
  • HY-128067
    5-(N,N-Hexamethylene)-amiloride

    Hexamethylene amiloride; HMA

    Sodium Channel HIV Apoptosis Cancer Infection
    5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) derives from an amiloride and is a potent Na +/H + exchanger inhibitor, which decreases the intracellular pH (pHi) and induces apoptosis in leukemic cells. 5-(N,N-Hexamethylene)-amiloride (Hexamethylene amiloride) is also an inhibitor of the HIV-1 Vpu virus ion channel and inhibits mouse hepatitis virus (MHV) replication and human coronavirus 229E (HCoV229E) replication in cultured L929 cells with EC50s of 3.91 μM and 1.34 μM, respectively.
  • HY-12946
    BI 653048

    Glucocorticoid Receptor Cytochrome P450 HCV Protease Infection Inflammation/Immunology
    BI 653048 is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC50 value of 55 nM. BI 653048 inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC50>30 μM). BI 653048 is extracted from patent WO2005028501A1 (Compound 103), is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus.
  • HY-12946A
    BI 653048 phosphate

    Glucocorticoid Receptor Cytochrome P450 HCV Protease Infection Inflammation/Immunology
    BI 653048 phosphate is a selective and orally active nonsteroidal glucocorticoid (GC) agonist with an IC50 value of 55 nM. BI 653048 phosphate inhibits CP1A2, CYP2D6, CYP2C9, CYP2C19 and CYP3A4 isoforms’ activity and reduces affinity for the hERG ion channel (IC50>30 μM). BI 653048 phosphate is extracted from patent WO2005028501A1 (Compound 103), is also a HCV NS3 protease inhibitor that can reduce viral loads infected with the hepatitis C virus.
  • HY-136379
    CID44216842

    Cdc42-IN-1

    Ras Cancer
    CID44216842 (Cdc42-IN-1) is a potent Cdc42-selective guanine nucleotide binding lead inhibitor. The EC50s for Cdc42 WT and Cdc42Q61L mutant are 1.0 and 1.2 μM in GTP binding assay, respectively. The EC50s for Cdc42 WT and Cdc42Q61L mutant are 0.3 and 0.5 μM in GDP binding assay, respectively. Use as a molecular probe.
  • HY-10238
    Danoprevir

    ITMN-191; R7227; RO5190591; RG7227

    HCV Protease HCV SARS-CoV Infection
    Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC50 of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC50 higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC50s=0.2-0.4 nM) as well as 2b and 3a (IC50s=1.6, 3.5 nM). Danoprevir is also a SARS-CoV 3CL pro inhibitor with an IC50 of 0.05 μM.